Varamir
DeskNewsCalendarSaved
Sign in · build your desk
NNVC

Nanoviricides, Inc.

Supply chain · Ownership · Earnings

OverviewSupply chainOwnershipNews
NewsCompanies A–ZMethodologySourcesCorrectionsTerms

Not investment advice. Not a broker-dealer. Prices: Intrinio (indices shown as ETF proxies). Supply-chain data CC BY 4.0; market data not redistributable.

Market
DeskNewsCalendarSaved
Reference
MethodologySourcesCorrectionsTerms
You
Theme
Sign in · build your desk
DeskNewsCalendarSaved

Changes

last 30 days
kindeventageactions
Sep 21optionsoptionsImplied move: ±54.1% into Oct 5 earnings (Sep 21 close).source12dsource

Who supplies Nanoviricides, Inc., and who buys from it

Nanoviricides, Inc. has 7 disclosed suppliers and 1 disclosed customer in SEC filings.

Who supplies Nanoviricides, Inc.?

7 disclosed

7 disclosed: Om Sai Clinical Research Private Limited, TheraCour, Aagami, Inc. and 4 more.

  1. 1—Om Sai Clinical Research Private Limited
  2. 2—TheraCour
  3. 3—Aagami, Inc.
  4. 4—Karveer Meditech Pvt. Ltd.
  5. 5—McCarter & English, LLP
  6. 6—TheraCour Pharma, Inc.
  7. 7—AR BioSystems

Who buys from Nanoviricides, Inc.?

1 disclosed

1 disclosed: Karveer Meditech Pvt. Ltd..

  1. 1—Karveer Meditech Pvt. Ltd.
NNVCNanoviricides, Inc.1.29▲ +0.39%
Earnings›Brief›

Intraday

▼ −0.39% since 7 AM
1.257 AM11 AM1 PM4 PMpre
1.261.271.281.291.29

High 1.29 7:00 am · Low 1.25 10:00 am ET

NNVC

Nanoviricides, Inc.

Supply chain · Ownership · Earnings

NYSE · Manufacturing

1.29
0.00 · 0.00%after closeafter hours
at close ▲ 0.00 · +0.39%
as of 20:00 UTC
open
1.29
volume
239,612
mkt cap
$32.7M
eps
-0.41
day range
1.25 – 1.29
1.28 sits 87 percent of the way through this range.
52-week
0.85 – 2.23
1.28 sits 32 percent of the way through this range.
next earningsNov 16 · in 44d · est.
EarningsExpected move · positioning · linked exposure›Briefprint›

Sources

sec edgar · verbatim disclosure

Sources for NNVC relationships

Show sources· 8›
  1. —Om Sai Clinical Research Private Limitedbuys from›
    “NanoViricides has retained Om Sai Clinical Research Private Limited, India, (Om Sai CRO) as the CRO for this Phase II clinical trial for Ebola in DRC.”

    10-K0001104659-26-111390filed Sep 28 '26

  2. —TheraCourbuys from›
    “In addition, TheraCour is the sole developer of our licensed products and we are required to pay TheraCour fees for indirect and direct costs incurred by TheraCour for its licensed products.”

    10-K0001104659-26-111390filed Sep 28 '26

  3. —Karveer Meditech Pvt. Ltd.sells to›
    “We have out-licensed NV-CoV-2 and NV-CoV-2-R for further clinical drug development and commercialization in the territory of India to KMPL, a company of which Dr. Anil Diwan is a passive investor and advisor, enabling KMPL to sponsor our drug products originally developed for COVID treatment, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies into Phase I human clinical trial.”

    10-K0001104659-26-111390filed Sep 28 '26

  4. —Aagami, Inc.buys from›
    “We have begun the process of actively seeking partnerships by retaining a consulting firm, Aagami, Inc., based in Illinois.”

    10-K0001104659-26-111390filed Sep 28 '26

  5. —Karveer Meditech Pvt. Ltd.buys from›
    “In consideration, KMPL will be reimbursed by us for all direct and indirect costs incurred for the clinical trials and development activities with a customary clinical trials manager fee of thirty (30%) of such costs and applicable taxes.”

    10-K0001104659-26-111390filed Sep 28 '26

  6. —McCarter & English, LLPbuys from›
    “NanoViricides was represented by McCarter & English, LLP while TheraCour was represented by DuaneMorris LLP.”

    10-K0001104659-26-111390filed Sep 28 '26

  7. —TheraCour Pharma, Inc.buys from›
    “Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, although these licenses do not specify the terms of milestone payments during clinical development that are customary in the pharmaceutical industry.”

    10-K0001104659-26-111390filed Sep 28 '26

  8. —AR BioSystemsbuys from›
    “The study was conducted at AR BioSystems in Tampa, FL.”

    10-K0001104659-26-111390filed Sep 28 '26

Supply chain

SEC · 8 direct ties

NNVC (Nanoviricides, Inc.) has 7 disclosed suppliers and 1 disclosed customers, strongest disclosure first.

Suppliers:

  1. Om Sai Clinical Research Private Limited, price pending
  2. TheraCour, price pending
  3. Aagami, Inc., price pending
  4. Karveer Meditech Pvt. Ltd., price pending
  5. McCarter & English, LLP, price pending
  6. TheraCour Pharma, Inc., price pending
  7. AR BioSystems, price pending

Customers:

  1. Karveer Meditech Pvt. Ltd., price pending
100%
expand

Distance from centre = disclosure strength · Extended: 2nd-degree ties, single companies only